{"filing":{"accession_number":"0001193125-26-346908","cik":"0002091349","ticker":"TRAX","company_name":"First Tracks Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"trax-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2091349/000119312526346908/trax-20260812.htm"},"events":[{"id":27248,"run_id":24820,"accession_number":"0001193125-26-346908","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"First Tracks issued a press release on August 12, 2026 announcing financial results for the three and six months ended June 30, 2026, including cash position ($168.0 million), R\u0026D expenses ($25.6M and $59.6M), G\u0026A expenses ($9.3M and $28.1M), and net loss ($33.4M and $83.9M). The filing explicitly states this is Item 2.02 disclosure with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes both financial statements and operational updates on clinical trial progress.","company_name":"First Tracks Biotherapeutics, Inc.","ticker":"TRAX","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28691,"accession_number":"0001193125-26-346908","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"First Tracks issued a press release on August 12, 2026 announcing financial results for the three and six months ended June 30, 2026, including cash position ($168.0 million), R\u0026D expenses ($25.6M and $59.6M), G\u0026A expenses ($9.3M and $28.1M), and net loss ($33.4M and $83.9M). The filing explicitly states this is Item 2.02 disclosure with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes both financial statements and operational updates on clinical trial progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:25:42.842431+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28691,"accession_number":"0001193125-26-346908","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"First Tracks issued a press release on August 12, 2026 announcing financial results for the three and six months ended June 30, 2026, including cash position ($168.0 million), R\u0026D expenses ($25.6M and $59.6M), G\u0026A expenses ($9.3M and $28.1M), and net loss ($33.4M and $83.9M). The filing explicitly states this is Item 2.02 disclosure with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes both financial statements and operational updates on clinical trial progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:25:42.842431+00:00","company_name":"First Tracks Biotherapeutics, Inc.","ticker":"TRAX","filing_date":"2026-08-12"}]}